Nephrosis
MONDO:0002331Pathological processes of the KIDNEY without inflammatory or neoplastic components. Nephrosis may be a primary disorder or secondary complication of other diseases. It is characterized by the NEPHROTIC SYNDROME indicating the presence of PROTEINURIA and HYPOALBUMINEMIA with accompanying EDEMA.
Also known as: Nephroses
71 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
CAR-T therapy aimed at tough kidney disease in kids — but trial never started
Disease control TerminatedThis was a planned early-stage trial to test whether anti-CD19 CAR-T cells could safely help children with multi-drug resistant nephrotic syndrome, a serious kidney condition. The study was withdrawn before any patients were enrolled, so no data on safety or effectiveness were co…
Phase: PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with tough kidney disease: obinutuzumab may replace steroids
Disease control OngoingThis study tests a new drug called obinutuzumab in 100 children aged 1-18 with refractory nephrotic syndrome, a kidney condition causing swelling and protein loss. The drug targets immune cells to reduce disease flares and dependence on steroids and other medications. Researchers…
Sponsor: Children's Hospital of Chongqing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could less steroid be just as good for kids with kidney disease?
Disease control OngoingThis study tests whether a lower dose of the steroid prednisone can treat relapses of nephrotic syndrome in children as effectively as the standard dose. Fifty children aged 1 to 18 with active relapses will be randomly assigned to either the reduced-dose or standard-dose regimen…
Phase: PHASE3 • Sponsor: The Hospital for Sick Children • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug shows promise for controlling rare kidney disorders
Disease control OngoingThis study tests the long-term safety and effectiveness of pegcetacoplan in 100 people with two rare kidney diseases, C3 glomerulopathy and IC-MPGN. Participants previously completed a one-year trial and saw benefit from the drug. The goal is to see if pegcetacoplan can keep redu…
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Can a common supplement shield dialysis Kids' hearts?
Disease control ENROLLING_BY_INVITATIONThis study tests whether a daily dose of alpha lipoic acid, an antioxidant supplement, can lower the risk of heart problems in 50 children who are on regular hemodialysis. Participants will either take the supplement or a placebo pill for a period, and researchers will monitor fo…
Phase: PHASE3 • Sponsor: Ain Shams University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for kids with kidney disease: drug may cut relapses and steroids
Disease control OngoingThis study tests a drug called obinutuzumab against a standard treatment (MMF) in children and young adults with a kidney condition that causes frequent relapses. The goal is to see if obinutuzumab can keep the disease in remission longer and reduce the need for steroids. About 8…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New hope for rare kidney disease patients: early access to pegcetacoplan
Disease control APPROVED_FOR_MARKETINGThis program provides early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that can lead to kidney failure. Participants must have active disease with significant protein in their urine. The goal is to offer a …
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Could a diabetes drug shield Kids' kidneys?
Disease control OngoingThis study tests whether dapagliflozin, a drug used in adults for diabetes and kidney protection, can reduce protein leakage in the urine of children with chronic kidney disease. Ten children aged 4 to 18 with persistent proteinuria despite standard therapy will take the drug, an…
Phase: NA • Sponsor: Al-Quds University • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Scientists hunt for genes behind kidney disease
Knowledge-focused OngoingThis study aims to find the genetic causes of kidney diseases like FSGS and nephrotic syndrome. Researchers will collect saliva and urine samples from up to 2,050 participants, including patients and their family members, as well as healthy volunteers. The goal is to understand w…
Sponsor: Beth Israel Deaconess Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Hidden calcium risk in Steroid-Treated kids
Knowledge-focused OngoingThis study looks at how often children with steroid-dependent nephrotic syndrome have high calcium levels in their urine (hypercalciuria). Researchers will check 50 children aged 2 to 16 who are on steroid treatment. The goal is simply to find out how common this condition is, no…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Which kidney test is more accurate? new study aims to find out
Knowledge-focused OngoingThis observational study compares two common blood tests—creatinine and cystatin C—to see which one better estimates actual kidney function in people with nephrotic syndrome. Researchers will use stored blood samples from 50 participants in three ongoing clinical trials. The goal…
Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:33 UTC
-
300 volunteers help create medical image bank for science
Knowledge-focused OngoingThis study gathers MRI, CT, and ultrasound images from 300 adults—some healthy, some with kidney or brain disease—to build a collection for future not-for-profit research. No new treatments are being tested; the goal is to make medical images available to scientists for advancing…
Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:28 UTC